ArticleAntimicrobial agents and chemotherapy2005
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 67 citations in OpenAlex.
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature · 2010Trial
- Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.Viruses · 2020Review
- Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Antimicrobial agents and chemotherapy · 2014Article
- Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Antimicrobial agents and chemotherapy · 2014Article
- Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles.Journal of virology · 2013Article
- Article
- Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.Antimicrobial agents and chemotherapy · 2012Article
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).Antimicrobial agents and chemotherapy · 2012Article
- New hepatitis C virus drug discovery strategies and model systems.Expert opinion on drug discovery · 2012Review
- Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.Antimicrobial agents and chemotherapy · 2012Article
- In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Antimicrobial agents and chemotherapy · 2012Article
- High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.PloS one · 2012Article
- Inhibition of dengue virus by targeting viral NS4B protein.Journal of virology · 2011Article
- Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.Antimicrobial agents and chemotherapy · 2011Article
- Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.Journal of virology · 2011Article
- Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.ACS medicinal chemistry letters · 2011Article
- Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrobial agents and chemotherapy · 2010Article
- Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.Current protocols in microbiology · 2010Article
- New oral HCV drug shows promise.Nature reviews. Microbiology · 2010Article
- Antiviral drugs: New oral HCV drug shows promise.Nature reviews. Drug discovery · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis C virus (HCV) replicon is a unique system for the development of a high-throughput screen (HTS), since the analysis of inhibitors requires the quantification of a decrease in a steady-state level of HCV RNA. HCV replicon replication is dependent on host cell factors, and any toxic effects may have a significant impact on HCV replicon replication. Therefore, determining the antiviral specificity of compounds presents a challenge for the identification of specific HCV inhibitors. Here we report the development of an HCV/bovine viral diarrhea virus (BVDV) dual replicon assay suitable for HTS to address these issues. The HCV reporter enzyme is the endogenous NS3 protease contained within the HCV genome, while the BVDV reporter enzyme is a luciferase enzyme engineered into the BVDV genome. The HTS uses a mixture of HCV and BVDV replicon cell lines placed in the same well of a 96-well plate and isolated in the same cell backgrounds (Huh-7). The format consists of three separate but compatible assays: the first quantitates the amount of cytotoxicity based upon the conversion of Alamar blue dye via cellular enzymes, while the second indirectly quantitates HCV replicon replication through measurement of the amount of NS3 protease activity present. The final assay measures the amount of luciferase activity present from the BVDV replicon cells, as an indicator of the specificity of the test compounds. This HCV/BVDV dual replicon assay provides a reliable format to determine the potency and specificity of HCV replicon inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.